LUND, Sweden, November 11, 2024 – Cellevate is excited to announce an exclusive global launch webinar on Wednesday, November 27, 2024. This event, held in collaboration with Cell & Gene Therapy Insights, will present the latest results from the validation program of Cellevate’s novel category of nanofiber-based cell culture systems designed for faster bioprocessing, more efficient scale up and increased viral vector yield and productivity.
Webinar Title: Revolutionizing Upstream Gene Therapy Manufacturing with Nanofiber Microcarriers
Date: Wednesday, November 27, 2024
Time: 07:00 PST | 10:00 EST | 15:00 GMT | 16:00 CET
For more details about the webinar and to register.
For more information, please contact:
Laura Chirica, PhD
CEO Cellevate
Email: laura.chirica@cellevate.com
About Cellevate
Cellevate is a Swedish biotech company based on proprietary nanofiber technology dedicated to building the next generation cell culture systems for cell- and gene therapy and novel vaccines biomanufacturing. The core nanotechnology, Cellevat3d® is a sustainable, deep-tech innovation for the biopharmaceutical industry. This platform allows for an industrial-scale production of a new category of nanofiber cell culture systems – with unparalleled surface area for cell growth, reproducibility, customization, and scalability, which ultimately lead to increased yield, productivity and process economy. Cellevat3d® nanofiber-based products are designed as an integrated part of upstream bioprocessing solutions, from laboratory to large-scale production.
For more information, please visit www.cellevate.com.